Order Online! Now! Get your $50 coupon for online order.
Get 50% off discount for CGT related product lines!
Our limited edition HOLIDAYS LLAMA is here! Place any order now to recieve one!
Earn Loyalty Rewards! Up to $155 Amazon Gift Card
Time Limited Offer: Welcome Gift for New Customers !
Time Limited Offer: Welcome Gift for New Customers !
5e5 of anti-EGFRvIII CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human EGFRvIII, His Tag (Cat. No. EGI-HP2H6) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). PE signal was used to evaluate the binding activity (QC tested).
Immobilized Anti-EGFRvIII Antibody , Human IgG1 at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human EGFRvIII Protein, His Tag (Cat. No. EGI-HF2H7) with a linear range of 0.625-5 μg/mL (QC tested).
The purity of Human EGFRvIII, Fc Tag (Cat. No. EGI-H5255) is more than 90% and the molecular weight of this protein is around 150-184 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Anti-EGFRvIII-CAR | EGFRvIII CAR; Anti-EGFRvIII-CAR | Phase 2 Clinical | National Cancer Institute, Kite Pharma | Glioblastoma; Brain Neoplasms; Gliosarcoma; Glioma | Details |
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) | LXF-821 | Phase 1 Clinical | University Of Pennsylvania, Novartis Pharma Ag | Glioblastoma | Details |
hEGFRvIII-CD3 Bi-scFv | Phase 1 Clinical | Duke University | Glioblastoma; Glioma | Details | |
EGFRvIII Targeted Chimeric Antigen Receptor CAR-T Cell Therapy (Chembrain) | Phase 1 Clinical | Chembrain Ltd | Glioblastoma; Glioma | Details | |
GNC-039 | GNC-039 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis | Details |
EGFRvIII-CAR | Phase 1 Clinical | Duke University Medical Center | Glioblastoma | Details | |
RO-7428731 | RO-7428731 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Glioblastoma | Details |
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) | CPGJ-602; 602; CPGJ602; CPGJ 602 | Phase 2 Clinical | Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd | Colorectal Neoplasms | Details |
Etevritamab | AMG-596 | Phase 1 Clinical | Amgen Inc | Glioblastoma | Details |
Anti-EGFRvIII-CAR | EGFRvIII CAR; Anti-EGFRvIII-CAR | Phase 2 Clinical | National Cancer Institute, Kite Pharma | Glioblastoma; Brain Neoplasms; Gliosarcoma; Glioma | Details |
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) | LXF-821 | Phase 1 Clinical | University Of Pennsylvania, Novartis Pharma Ag | Glioblastoma | Details |
hEGFRvIII-CD3 Bi-scFv | Phase 1 Clinical | Duke University | Glioblastoma; Glioma | Details | |
EGFRvIII Targeted Chimeric Antigen Receptor CAR-T Cell Therapy (Chembrain) | Phase 1 Clinical | Chembrain Ltd | Glioblastoma; Glioma | Details | |
GNC-039 | GNC-039 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis | Details |
EGFRvIII-CAR | Phase 1 Clinical | Duke University Medical Center | Glioblastoma | Details | |
RO-7428731 | RO-7428731 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Glioblastoma | Details |
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) | CPGJ-602; 602; CPGJ602; CPGJ 602 | Phase 2 Clinical | Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd | Colorectal Neoplasms | Details |
Etevritamab | AMG-596 | Phase 1 Clinical | Amgen Inc | Glioblastoma | Details |
This web search service is supported by Google Inc.